 |
 |
|
1 January 1998 | Volume 128 Issue 1 | Pages 56-63
In this paper, cost and effectiveness data for six clinical interventions are applied simultaneously to a hypothetical population of 100 000 patients to show how selecting guidelines to maximize overall population benefit compares with selecting the best guidelines for individual patients.By entering effectiveness (added survival) and cost information from recent prevention, screening, diagnostic, and therapeutic guidelines into a computer-based optimization model, the options that maximized overall population effectiveness while keeping additional cost within varying specified constraints were identified.
In 57% of selection opportunities, the clusters of guidelines that yielded maximum population benefit differed from those that maximized benefit for individual patients.Some choices were more stable than others over ranges of cost constraints.
Clinical practice guidelines chosen to maximize cost-effectiveness for individual patients often do not maximize cost-effectiveness for populations of patients. To allocate resources as efficiently as possible, decision makers should consider other sources of information in addition to the recommendations of specific practice guidelines. "Robust" guidelines that simultaneously address both individual and societal health benefit should be sought.
Author and Article Information
From Yale School of Medicine, New Haven, Connecticut; and University of Pennsylvania School of Medicine and the Wharton School, Philadelphia, Pennsylvania.
MEDICINE AND PUBLIC ISSUES
Competing Practice Guidelines: Using Cost-Effectiveness Analysis To Make Optimal Decisions
Disclaimer: This paper, including the optimization model, was developed before Dr. Granata's affiliation with Oxford Health Plans, solely as an academic project to further research in cost-effectiveness analysis and health policy. There is no direct or indirect relation between the development or content of the paper and Oxford Health Plans or any other medical care system.
Grant Support: During this project, Dr. Granata was supported in part by Bridgeport Hospital (Bridgeport, Connecticut) while at the Wharton Executive MBA Program from 1992 to 1994.
Requests for Reprints: Attilio V. Granata, MD, MBA, Oxford Health Plans, 48 Monroe Turnpike, Trumbull, CT 06611.
Current Author Addresses: Dr. Granata: Oxford Health Plans, 48 Monroe Turnpike, Trumbull, CT 06611.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. Sharifi, H. Sharifi, S. Morshed, K. Bozic, and M. Diab Cost-Effectiveness Analysis of Periacetabular Osteotomy J. Bone Joint Surg. Am., July 1, 2008; 90(7): 1447 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Bell, D. R Urbach, J. G Ray, A. Bayoumi, A. B Rosen, D. Greenberg, and P. J Neumann Bias in published cost effectiveness studies: systematic review BMJ, March 25, 2006; 332(7543): 699 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Piette and E. A. Kerr The impact of comorbid chronic conditions on diabetes care. Diabetes Care, March 1, 2006; 29(3): 725 - 731. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Blay, S. Bonvalot, P. Casali, H. Choi, M. Debiec-Richter, A. P. Dei Tos, J.-F. Emile, A. Gronchi, P. C. W. Hogendoorn, H. Joensuu, et al. Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann. Onc., April 1, 2005; 16(4): 566 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Berghmans, M Berg, M van den Burg, and R ter Meulen Ethical issues of cost effectiveness analysis and guideline setting in mental health care J. Med. Ethics, April 1, 2004; 30(2): 146 - 150. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Earnshaw, A. Richter, S. W. Sorensen, T. J. Hoerger, K. A. Hicks, M. Engelgau, T. Thompson, K. M. V. Narayan, D. F. Williamson, E. Gregg, et al. Optimal Allocation of Resources Across Four Interventions for Type 2 Diabetes Med Decis Making, October 1, 2002; 22(5_suppl): S80 - S91. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. McQueen Overview of Evidence-based Medicine: Challenges for Evidence-based Laboratory Medicine Clin. Chem., August 1, 2001; 47(8): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Lim, T. F. Anderson, M. Douglass, J. Koo, M. Lebwohl, W. Morison, C. Taylor, M. Zanolli, S. Chen, and A. M. Garber Cost-effectiveness of Methotrexate and Goeckerman Therapy: A Flawed Analysis Arch Dermatol, June 1, 1999; 135(6): 717 - 718. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cook and M. Giacomini The Trials and Tribulations of Clinical Practice Guidelines JAMA, May 26, 1999; 281(20): 1950 - 1951. [Full Text] [PDF]
|
|
|
|
|
|
The CDC Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for Type 2 Diabetes JAMA, November 25, 1998; 280(20): 1757 - 1763. [Abstract] [Full Text] [PDF]
|
|
Article
